The primary objective is to investigate the association between temporal evolutions of blood biomarkers and clinical adverse events, in order to produce a dynamic, individual, and accurate prediction model for patients with HFpEF.
Moreover several secondary objectives will be investigated.
Age of 18 years or older
Capable of understanding and signing informed consent
A diagnosis of HFpEF according to the HFA-PEFF diagnostic algorithm of the ESC or/and a high (90%) probability of HFpEF according to the H2FPEF score, i.e. a score of 6 or higher.
History of LVEF ≤40%
Scheduled for surgery or intervention for both coronary and non-coronary indication within 6 months of inclusion
Impaired renal function, defined as eGFR < 20 mL/min/1.73 m2 (CKD-EPI) or requiring dialysis at the time of screening
Acute or chronic liver disease, defined by serum levels of transaminases or alkaline phosphatase more than three times the upper limit of normal at screening
Erasmus Medical Center
Lead sponsor
Ikazia Hospital, Rotterdam
Collaborator
Franciscus Gasthuis & Vlietland (Hospital)
Collaborator
OLVG
Collaborator
Universitair Ziekenhuis Brussel
Collaborator
Noordwest Ziekenhuisgroep
Collaborator